cerebrolysin-instruction
cerebrolysin-instruction

CEREBROLYSIN ®

Clear
Bulk deal
Quantity Discount Discounted price
2 5% -
3 8% -
4 10% -
5 12% -
6 14% -
7 16% -
8 + 18% -
Bulk pricing will be applied to package:

Buy Cerebrolysin peptide with 37 day fast domestic delivery within the US ($5) just choose “Ships from: US (+15%)”

Cerebrolysin is a neuropeptide preparation with neuroprotective and neurorestorative effects that comes in an injection form in 2 ml, 5 ml, and 10ml ampoules. It is based on low molecular weight biologically active neuropeptides (20%) and amino acids (80%) isolated from porcine brain tissue by enzymatic cleavage. For more information on the composition read this article.

The drug was created in 1949 by Gerhart Harrer, an Austrian Professor, and approved on 1 August 1954. After many success stories, extensive research, and the discovery of neurotrophic regulation, its popularity has increased drastically. It is registered in more than 50 countries, mostly in Europe and Asia. In Austria, the homeland of Cerebrolysin, it’s listed in the Neurorehabilitation after stroke guidelines. In Russia, it is included in the Anti-dementia plan for 2025 under the Ministry of Healthcare of the Russian Federation.

Cerebrolysin is used in the following cases:

  • Strokes and stroke complications;
  • Alzheimer’s disease and other types of dementia;
  • Traumatic brain injuries;
  • Spinal cord injuries;
  • ADHD in children;
  • Antidepressant-resistant depressions;
  • Other cerebral diseases.

 

Alternatives to Cerebrolysin: Memoprove, Cortexin.

Here is one of the customer’s reviews on Reddit.

Personal experience of a well-known nootropic enthusiast and personal health coach:

Produced by EVER Pharma, Austria. Read more about the producer in this blog post. Here is the original 84-pages Cerebrolysin Monograph by EverNeuro Pharma, where you can find a lot of information.

Check the Full Information on Cerebrolysin with a FAQ Section!


Legal Disclaimer
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease. See more

Dosage and administration

Cerebrolysin has indication-specific dosing, with the most common regime being intramuscular injections of 5 ml once daily. Studies indicate that Cerebrolysin was also used subcutaneously, though the dosages were 0.5–1.0 ml and the effectiveness was lower.

Please refer to this article for more detailed dosage instructions.

Please use sterile needles, sterilize the administration site, wear sterile plastic gloves, administer as soon as you opened the vial. Please relax your muscle and inject slowly.

Contraindications

Cerebrolysin should be used with caution by those who are taking antidepressants and MAO-inhibitors, or have kidney issues.

Side effects

Cerebrolysin has an excellent safety record. Unless taken in large amounts (>10 ml), the side effects are rare and may include fatigue, headaches, dizziness, and insomnia.

Storage conditions

Please keep at room temperature – there is no need to keep Cerebrolysin in a fridge. Protect from light (in the carton). Keep in a safe place out of reach of children.
Shelf life is 5 years. Do not use beyond the expiration date printed on the package.

Manufacturer

EVERPharma GmbH, Austria.

OFFICIAL INSTRUCTION

  1. Rutheret al (1994) Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with Senile Dementia of the Alzheimer Type (SDAT) https://www.ncbi.nlm.nih.gov/pubmed/8159781
  2. L. Francis-Turner, V. Valouskova (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study https://www.ncbi.nlm.nih.gov/pubmed/8848264
  3. Schwab et al (1997) Morphofunctional effects of moderate forebrain ischemia combined with short-term hypoxia in rats – protective effects of Cerebrolysin https://www.ncbi.nlm.nih.gov/pubmed/9085071
  4. V. Valouskova and A. Gschanes (1999) Effects of NGF, b-FGF, and Cerebrolysin on Water Maze Performance and on Motor Activity of Rats: Short- and Long-Term Study https://www.ncbi.nlm.nih.gov/pubmed/10082636
  5. Masliah et al (1999) Cerebrolysin Ameliorates Performance Deficits, and Neuronal Damage in Apolipoprotein E-Deficient Mice https://www.ncbi.nlm.nih.gov/pubmed/9972690
  6. Bae et al (2000) A Double-Blind, Placebo-Controlled, Multicenter Study of Cerebrolysin for Alzheimer’s Disease https://www.ncbi.nlm.nih.gov/pubmed/11129744
  7. Ruther et al (2000) Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy https://www.ncbi.nlm.nih.gov/pubmed/11005546
  8. Ruether et al (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/11552768
  9. Hartbauer et al (2001) Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neurons https://www.ncbi.nlm.nih.gov/pubmed/11475013
  10. Hartbauer et al (2001) Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons https://www.ncbi.nlm.nih.gov/pubmed/11459078
  11. Eder et al (2001) Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: An immunohistochemical study on aged rats https://www.ncbi.nlm.nih.gov/pubmed/12197668
  12. Panisset et al (2002) Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent https://www.ncbi.nlm.nih.gov/pubmed/12111446
  13. Rockenstein et al (2003) The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance https://www.ncbi.nlm.nih.gov/pubmed/14628195
  14. Ladurner et al (2004) Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial https://www.ncbi.nlm.nih.gov/pubmed/15583955
  15. Alvarez et al (2006) A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/16420392
  16. Rockenstein et al (2006) Cerebrolysin Decreases Amyloid-b Production by Regulating Amyloid Protein Precursor Maturation in a Transgenic Model of Alzheimer’s Disease https://www.ncbi.nlm.nih.gov/pubmed/16511867
  17. Wei et al (2007) Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/17318304
  18. Ren et al (2007) Cerebrolysin enhances functional recovery following focal cerebral infarction in rats https://www.ncbi.nlm.nih.gov/pubmed/17473393
  19. Alvarez et al (2008) Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate–severe traumatic brain injury https://www.ncbi.nlm.nih.gov/pubmed/18273537
  20. Muresanu et al (2008) A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration https://www.ncbi.nlm.nih.gov/pubmed/18048059
  21. Alvarez et al (2009) Reduced TNF-a and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent Cerebrolysin https://www.ncbi.nlm.nih.gov/pubmed/19531281
  22. Sharma et al (2010) Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat https://www.ncbi.nlm.nih.gov/pubmed/20633118
  23. Guekht et al (2011) Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial https://www.ncbi.nlm.nih.gov/pubmed/20656516
  24. Alcantara-Gonzalez et al (2012) Combined Administration of Cerebrolysin and Donepezil Induces Plastic Changes in Prefrontal Cortex in Aged Mice https://www.ncbi.nlm.nih.gov/pubmed/22826038
  25. Heiss (2012) Cerebrolysin in Patients With Acute Ischemic Stroke in Asia Results of a Double-Blind, Placebo-Controlled Randomized Trial https://www.ncbi.nlm.nih.gov/pubmed/22282884
  26. Menon et al (2012) Cerebrolysin, a Mixture of Neurotrophic Factors Induces Marked Neuroprotection in Spinal Cord Injury Following Intoxication of Engineered Nanoparticles from Metals https://www.ncbi.nlm.nih.gov/pubmed/22229324
  27. Chen et al (2013) Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study https://www.ncbi.nlm.nih.gov/pubmed/23656173
  28. Amiri-Nikpour et al (2014) Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke https://www.ncbi.nlm.nih.gov/pubmed/25516711
  29. Muresanu et al (2015) Cerebrolysin and Recovery After Stroke (CARS) A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial https://www.ncbi.nlm.nih.gov/pubmed/26564102
  30. Ziganshina et al (2016) Cerebrolysin for acute ischaemic stroke https://www.ncbi.nlm.nih.gov/pubmed/27918088

Related products

COGITUM ®

$ 120.00$ 138.00

Cogitum is an adaptogen with tonic and stimulating properties. It has a 40-year-long track record of successful application. Cogitum is widely used in pediatrics and child neurology for treating delayed development, asthenic syndrome and for increasing endurance and mental performance in children and adolescents during high loads. It enhances memory due to D-Aspartic acid which is a well-known metabolite.

Caffeine is a substance that in its natural form is produced in the leaves and seeds of many plants. Caffeine stimulates the central nervous system, increases mental and physical performance, physical activity, shortens the reaction time, temporarily reduces fatigue and drowsiness, facilitates perception, increases heat production and urination, increases gastric secretion. It may be used as an extra energy source in the morning, as well as to stay productive during the day.

BEMITIL ® (Metaprot)

$ 25.00$ 28.50

Bemitil has a long history of usage in clinical practice and in sport. It is the reference drug of actoprotectors class. Actoprotectors are the substances that are intended to improve physical performance of people exposed to stressful conditions, such as high physical loads, heat exposure, and hypoxia. It is often used recreationally to improve cognitive functions and physical performance.

A perfect alternative for the discontinued Ladasten (Bromantane)

ARBIDOL ® (Umifenovir)

$ 26.00$ 50.00

Arbidol is a broad-spectrum antiviral compound developed in USSR in 1974. Arbidol demonstrates activity against a number of enveloped and non-enveloped viruses. It is used for the prevention and treatment of influenza and other acute respiratory viral infections in adults and children.В Arbidol may also be immunomodulatory, and as such be capable of interferon induction and/or macrophage activation.